ArticleApoptosis : an international journal on programmed cell death2026
Silencing SLC52A2 promotes tertiary lymphoid structure formation and inhibits IL-17 pathway to ameliorate melanoma progression.
Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Tertiary lymphoid structure (TLS) correlates with improved prognosis in melanoma. The role of solute carrier family 52 member A2 (SLC52A2) in mediating this interplay and influencing melanoma progression remains unclear. Integrated bioinformatics analysis of melanoma datasets (GSE3189, GSE19234, GSE46801, GSE4587, GSE238207, GSE53223) were applied to identify TLS-associated candidate genes. Machine learning was performed to screen key genes validated in independent cohorts and clinical blood samples. In vitro functional assays and in vivo syngeneic models assessed the impact of SLC52A2 knockdown. TLS-related indicators were evaluated by immunohistochemistry, multiplex immunofluorescence (mIF), flow cytometry, and enzyme-linked immunosorbent assay. Furthermore, the downstream pathway of SLC52A2 was identified by bioinformatics analysis. CD8⁺ T cell depletion and pathway feedback experiments were conducted to validate mechanistic dependencies. Herein, SLC52A2 was identified as a key hub gene associated with TLSs. Silencing SLC52A2 significantly inhibited melanoma cell proliferation, migration, and invasion in vitro, and suppressed tumor growth in vivo, reducing Ki67 expression. SLC52A2 knockdown enhanced TLS formation, evidenced by increased CD4/CD20/CD68 infiltration, elevated CD3+/CD8+ T-cell infiltration with enhanced cytotoxic function (granzyme B⁺ and interferon-γ⁺), and upregulated TLS-organizing chemokines. mIF and quantitative TLS scoring confirmed significantly increased TLS abundance and maturity upon SLC52A2 silencing. Depletion of CD8⁺ T cells reversed both the TLS enhancement and the tumor-suppressive effects induced by SLC52A2 silencing. Mechanistically, interleukin (IL)- 17 signaling pathway was screened as the downstream pathway of SLC52A2. Experimentally, SLC52A2 knockdown reduced IL-17A/IL-17RA protein levels, and IL-17 receptor antagonist LY3509754 exhibited the anti-tumor role in vitro. Collectively, SLC52A2 drives melanoma progression by inhibiting TLS-mediated anti-tumor immunity and activating the IL-17 pathway, positioning SLC52A2 as a promising therapeutic target for melanoma.
Indexed as
Identifiers
42671664What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.